The particle size distribution (PSD) and the stability of nanoparticles enabled medicinal products (NEP) in complex biological environments are key attributes to assess their quality, safety and efficacy. Despite its low resolution, dynamic light scattering (DLS) is the most common sizing technique since the onset of NEP in pharmaceutical technologies. Considering the limitations of the existing sizing measurements and the challenges posed by complex NEPs both scientists and regulators encourage the combination of multiple orthogonal high-resolution approaches to shed light in the NEP sizing space (e.g. dynamic light scattering, electron microscopy, field flow fractionation coupled to online sizing detectors, centrifugal techniques, particle tracking analysis and tunable resistive pulse sensing). The pharmaceutical and biotechnology developers are now challenged to find their own pragmatic characterisation approaches, which should be fit for purpose and minimize costs at the same time, in a complicated landscape where only a few standards exist. In order to support the community, the European Nanomedicine Characterisation Laboratory (EUNCL) and the US National Cancer Institute Nanotechnology Characterization Laboratory (NCI-NCL) have jointly developed multiple standard operating procedures (SOPs) for NEP assessment, including the measurements of particle size distribution, and are offering wide access to their 'state of the art' characterisation platforms, in addition to making SOPs publicly available. This joint perspective article would like to present the NCI-NCL and EUNCL multistep approach of incremental complexity to measure particle size distribution and size stability of NEPs, consisting of a quick preliminary step to assess sample integrity and stability by low resolution techniques (pre-screening), followed by the combination of complementary high resolution sizing measurements performed both in simple buffers and in complex biological media. Test cases are presented to demonstrate: i) the need for employing at least one highresolution sizing technique, ii) the importance of selecting the correct sizing techniques for the purpose, and iii) the robustness of utilizing orthogonal sizing techniques to study the physical properties of complex NEP samples.
Introduction
The application of nanotechnology in healthcare has a tremendous potential to address a variety of medical conditions by providing better diagnostics and therapy. A broad range of nanoparticles enabled medicinal products (NEP) have been investigated for medical applications, including liposomes, polymeric nanoparticles, lipid-based nanoparticles, micelles, nanocrystals, metal colloids, metal oxides, and many others [1] . Unfortunately, when compared to the extensive research activities in research laboratories and industries (e.g., SMEs and MNs), the clinically approved nanomedicines are still very limited [2] . Among the extensive number of NEP published in literature, only about 50 candidates have successfully crossed the "valley of death", and thus translated from the research laboratories to scale up approved product for use in clinical setups. Very often NEPs fail to reach late clinical phases due to the lack of pre-clinical characterisation protocols, which are needed to correlate their physico-chemical properties with their biological effects [1, 3, 4] . If compared to "classical" small molecule drugs, the assessment of the quality, safety and efficacy profiles of NEPs demands the investigation of many additional physico-chemical properties, including their chemical composition, average particle size and polydispersity, dispersion stability, particle shape, surface charge, drug loading and drug release, surface coating and hydrophobicity [1] [2] [3] 5] . Moreover, the physico-chemical properties of NEP, including the size, physical and chemical stability, surface properties and drug release profile, need to be investigated, not only in their original formulation, but also when dispersed in biological complex environments, since different pH, high ionic strengths and the interactions with plasma can modify the physical properties of the particles, thus influencing their safety and efficacy profiles [3, 6, 7] . To complicate matters even more, the uniqueness of every NEP imposes a different methodological approach to characterise its physical-chemical properties. In this context, the development of reliable pre-clinical characterisation strategies and of suitable standard protocols is a critical step to determine the safety and quality of each emerging NEP to sustain the safe industrial development of nanomedicines. This robust and comprehensive pre-clinical characterisation has been strongly requested by the public authorities, regulatory bodies and agencies funding R&D, with the aim to translate successful NEP candidates from the laboratories to the clinic [2] [3] [4] . Guidelines and reflection papers describing the pre-clinical charaterisation needs of NEPs have been published by regulatory agencies, including the European Medical Agency (EMA) [8] [9] [10] and the US Food and Drug Administration (FDA) [7, 11] . Recently, a review from Halamoda-Kenzaoui et al. has mapped the available standards against the regulatory needs for NEPs pre-clinical characterisation, underlining the currents needs, and also presenting the importance and the ongoing effort to cover the regulatory gaps by developing new standards for NEPs [4] .
In this context, the US National Cancer Institute Nanotechnology Characterization Laboratory (NCI-NCL) and, since 2015, the European Nanomedicine Characterisation Laboratory (EUNCL) have been established to unbiasedly support the developers of NEP. EUNCL and NCI-NCL are providing a multi-disciplinary infrastructure which provides a comprehensive set of preclinical tests (physical, chemical, in-vitro and in-vivo biological testing). The two laboratories work together and also in tight collaboration with regulatory bodies and metrology institutes, in order to develop SOPs for the assessment of NEP which are relevant for regulatory purposes and to promote a harmonized approach between Europe and the USA. Their testing strategy allows researchers to determine, and fully understand, the immunological effects, biodistribution, pharmacokinetics, metabolism and safety profiles of their nanoparticles, in order to detect early fails and to accelerate the translation of promising products to clinical investigation for safety (Phase I clinical trial). All the SOPs developed by the two laboratories are published on their website (https://ncl.cancer.gov/resources/assaycascade-protocols, http://www.euncl.eu/about-us/assay-cascade/). In addition, several articles are available where lessons learned and knowledge are shared with the scientific community [3] [4] [5] [6] 12, 13] .
From this close interaction, it emerged that average particle size, particle size distribution (PSD) and aggregation behaviors in complex biological media are, among others, critical quality attributes for the preclinical characterisation of NEP [3, 5, [14] [15] [16] [17] . In fact, they influence the body absorption, biodistribution and excretion, during their pharmacological targeting and off targets effects [1, 18, 19] . Importantly, the particle size and polydispersity can significantly change due to interactions of plasma proteins with the NEP surface. In biological media NEPs may aggregate increasing the average population size and even sediment or, on the contrary, aggregation may be reduced, or they can start to degrade, producing populations of smaller particles.
Due to the key role in determining the efficacy and safety of NEP [1] , particle size, polydispersity and size stability should be controlled in simple and in biological media from the early development stages, ideally from their design. At later stages, e.g. during routine manufacturing, average size and polydispersity are key attributes to be controlled for quality purposes. According to the regulators' guidelines, including EMA [8] [9] [10] and FDA [7, 11] , the NEP developers should not only characterise the particle size distribution of their products immediately after their synthesis, but also study i) the reproducibility of the manufacturing procedure (batch to batch consistency), ii) the long term stability of the formulation during storage, iii) measure the nanoparticle size in the final product administered to the patient and finally iv) analyze the changes of size and shape of the NEP after being in contact with physiological media (e.g., interactions with serum proteins) [3] .
Many techniques are being used to measure the size distribution of nanoparticle formulation in medicinal products, including electron microscopy (EM), laser scattering techniques (e.g. dynamic and static light scattering, laser diffraction), field flow fractionation (FFF) coupled to multiple sizing detectors, centrifugal techniques (e.g. analytical ultracentrifugation and centrifugal particle sedimentation), tunable resistive pulse sensing (TRPS) and particle tracking analysis (PTA). However only a few standards for size measurements of NEP are available, while many are still under development [4] . Based on a recent analysis [1] of the dossiers presented to the FDA from 1973 to 2015, dynamic light scattering (DLS) has been the most recurrently used sizing technique by nanomedicine stakeholders (48% of reporting applications), followed by laser diffraction and microscopy which are adopted in 30% and 14% of the applications. Only approximately 8% of the applicants have characterized their products by other complementary sizing techniques, e.g. gel permeation chromatography, asymmetrical flow field-flow fractionation, and centrifugation measurements. DLS is recognized to be a low-resolution method, which is only suitable for an initial check of the sample. However, in order to avoid misleading results, it is not recommended to apply DLS as the only method for the pre-clinical characterisation of complex NEPs [3, [20] [21] [22] . On the contrary, the combination of multiple high-resolution techniques is often required to understand the PSD of NEPs, especially when dispersed in complex biological media. In fact, most of the times NEP samples are polydispersed and it is necessary to resolve multiple populations which slightly differ in size and shape, to differentiate the presence of small aggregates from larger particles, or to quantify a small amount of very big aggregates. Unfortunately, the article by D'Mello et al. demonstrates that particle size distribution in the nanomedicine field is often still only measured by low resolution DLS measurements, possibly due to its low costs and simplicity in use. Recently both scientists and regulators have started to encourage the use of high resolution approaches and suggested to combine orthogonal measurements in order to better characterise the behavior of NEP systems, leading to more accurate and realistic assessment for sizing and concentrations [3, 7] . Despite these efforts, the co-authors believe that there is still a strong urgency to educate the community on the drawbacks of batch mode DLS and to support the development of new reliable high-resolution approaches for the accurate characterisation and evaluation of particle size distribution.
It is the intention and objective of this perspective to discuss the current state of the art of sizing measurements, comparing the available instrumental capability and their suitability to characterise challenging NEP systems. In this context, we would like to present the NCI-NCL and EUNCL joint strategy to analyze the particle size distribution of NEPs, which is built in a complexity ladder (e.g., three steps of incremental complexity), as shown in Fig. 1 . Practical examples are presented in order to show the suitability of the strategy developed at EUNCL and NCI-NCL to measure poly-dispersity, detect dimers and aggregates, measure batch to batch consistency and identify size changes in presence of plasma proteins. It is important to point out that this review is intended to cover the characterisation of injectable formulations; complex biomaterial or hydrogel embedded nanoparticles with localised delivery are not included.
State of the art techniques for measuring nanoparticle size distribution
Knowledge on the state-of-the-art instrumentations, techniques, and capabilities for the characterisation of NEPs, is one of the key aspects that EUNCL and NCI-NCL have jointly developed and put into practice across the many samples assessed. Table 1 provides a qualitative comparison of multiple sizing methods applicable to injectable formulations, their range of applicability and limitation for the measurement of PSD and morphology of NEPs (e.g. working size range, resolution of polydispersity, detection of small and big aggregates, ability to measure not spherical particles), cost and complexity.
Other orthogonal sizing techniques, including small angle X-ray scattering (SAXS) [22] [23] [24] , atomic force microscopy (AFM) [25] , and single particle ICP-MS (sp-ICP-MS) [26] may also be applicable in measuring PSD and particle concentration according to the nature of the NEPs. However, we decided to only focus on the sizing techniques which are most currently used in NCI-NCL and in EUNCL, in order to provide their direct experience.
Batch methods: dynamic light scattering
Dynamic light scattering (DLS) measures the correlation of the timedependent fluctuations in the light scattered by a suspension of nanoparticles (autocorrelation function), which is determined by their Brownian motion. The nanoparticle diffusion coefficient(s) is then calculated by fitting the autocorrelation function and used to determine the hydrodynamic diameter (or radius) of the particles via the Stokes Einstein equation. The analysis assumes that the object measured is of spherical shape and requires that the viscosity of the solution is known.
DLS is a very fast and inexpensive analysis that does not require highly specialized personnel. For this reason, it is considered the entry point measurement for particle sizing of NEPs and accepted worldwide by the regulators. As stated, DLS is commonly used in the nanomedicine, under "batch" mode, which possesses very important limitations for the analysis of polydispersed samples, and could be considered a low-resolution method [3, [20] [21] [22] . In fact, as results of the dependence of scattering intensity on the particle size to the sixth power, a small number of large particles often masks the smaller ones. Therefore, batch mode DLS is a useful user-friendly method to assess sample integrity and the stability of a nanoformulation when exposed to highly concentrated salts, unsuitable pH or to the presence of plasma [27, 28] . However, when it measures the PSD of polydispersed samples, it often produces misleading results. In fact, it is often not able to distinguish between the PSD of polydispersed samples made of two or three particle populations in similar size ranges [3, 21, 22, 29] , it is unable to distinguish between small aggregates and larger particles [20] and cannot reliably measure the PSD of NEPs in presence of plasma proteins [3, 30] . Step by step approach of incremental complexity based on three tiers. The purpose of each step is described and some of the sizing techniques which may be fit for that purpose, according to the specific properties of the NEP under investigation, are listed.
For more details on the DLS technique, a recent work published by Maguire and coworkers highlighted the principles, the parameters and reasons influencing the nanoparticle size-measurement size [22] .
Separation particle sizing methods
The resolution of the obtained particle size distribution significantly increases if a fractionation step is introduced prior to sizing measurements, in order to separate the particles composing a NEP sample according to their size. This approach could help to go beyond the limits of batch mode DLS.
Asymmetric field flow fractionation
Field-Flow Fractionation (FFF) is a family of flow-based separation methods. Similar to size exclusion chromatography (SEC), in FFF the sample is injected into a liquid stream flowing through a separation channel. However, the FFF channel does not contain packing or stationary phase. Most FFF channels are parabolic flow profile chambers where the retention and separation are generated by an external force, such as a perpendicular liquid flow or centrifugal force [31] .
In asymmetric flow field flow fractionation (AF 4 ) the separation is generated by a cross flow applied perpendicularly to the elution flow, which passes through a porous membrane at the bottom of the channel (accumulation wall). In this gentle fractionation process smaller particles are eluted faster than the larger ones and exit the separation channel first. AF 4 has been successfully applied to many NEP systems including metal oxides, metallic nanoparticles, lipid NPs, liposomes, virus like particles and polymeric NPs, as reviewed by many authors [3, [32] [33] [34] [35] [36] . AF 4 NP-sorting coupled to online sizing DLS and/or multiangle light scattering (MALS) is a very powerful and robust sizing technique which allows measurement of the PSD of polydispersed NEPs and the determination of small changes in particle size, e.g. to control batch to batch consistency and stability of NEPs [3, [32] [33] [34] [35] [36] . Moreover, the separation of NEPs from plasma proteins allows to study the modifications of PSD in a biologically relevant environment [3] . Interestingly, AF 4 can provide additional information than just size measurements for NEP systems, by coupling multiple detector combinations online to the AF 4 channel. The ratio between the geometric radius derived by the MALS detector and hydrodynamic radius derived by the DLS, can provide indirect indications of the particle shape (spherical vs elongated particles). MALS, in combination with a differential refractive index detector can be used to analyze the molecular weight of polymeric samples [35, 37] . Online ICP-MS detectors can be used to measure the chemical composition and impurities of inorganic particles. Finally, qualitative information of the drug loading of active pharmaceutical ingredients which absorb in the UV-VIS, may be derived by coupling also an UV-VIS detector to the system. AF 4 has also some disadvantages: the instruments are rather complex and require experienced operators to perform reliable measurements. Measurements conditions cannot be standardized, since each NEP sample may require a specific and often laborious method optimization, as described in [31] . One common problem that may arise is the loss of sample in the channel due to the irreversible interactions of NEP with the semipermeable membrane, which is very common in the case of positively charged samples. However, if an elution method for a specific NEP is developed and validated, AF 4 -MALS-DLS is a very robust and powerful tool to monitor the sample stability, for synthesis optimization and for quality control purposes [3] .
Centrifugation based techniques
Differential centrifugal sedimentation (DCS) [14, 38] and analytical ultracentrifugation (AUC) [39] [40] [41] [42] fractionate the particles due to their mass (determined by their size and density). The analysis is based on sedimentation experiments, which measures the transport of particles in solution under the influence of a strong centrifugal force. For spherical particles of homogeneous (known) density, the particle size (e.g.
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the stoke diameter) is calculated from their sedimentation time. In polydispersed samples, different components sediment at different times, and therefore can be detected separately during a single measurement. In DCS instruments, the particles sediment in an optically clear disk, where a density gradient has been generated to stabilize the sedimentation. When the particles reach the outside edge of the disk, they change the scattered light portion of a monochromatic light source. The change of the scattering light vs time is continuously measured and then transformed into an intensity-based particle size distribution. AUC set up is slightly different. During an AUC measurement, the sample is left to sediment in an optically clear quartz or Safire cell, which is fixed into the AUC rotor. The centrifugation force generates a concentration profile over the cell radial position c(r), which changes with time. During the measurement, the concentration profile is continually scanned inside the cell in the radial direction and measured by multiple detectors (e.g. interference and absorbance optics) generating a concentration distribution of the sample suspension c(r,t). This distribution is then analyzed by multiple models to determine the sedimentation coefficient c(s) distributions of the sample, and finally converted to mass metric particle size distributions.
Even if DCS and AUC techniques are based on the same sedimentation principle, the range of the rotational speed achieved by DCS and AUC instrumentation is different, thus the two techniques possess different detectable size ranges. Maximum speed achieved by DCS is lower than AUC, limiting the smaller detectable size to 5 nm for dense particles like metallic NPs, and to size > 20 nm for less dense particles (silica, polymeric particles, liposomes, etc.) [38] . AUC can achieve very high centrifugal forces (> 100,000 g) allowing to analyze very small objects, including proteins, polymers, small molecules and very small nanoparticles with the resolution of 1 nm or less. On the other hand, large objects may sediment too quickly to be analyzed by AUC, while DCS is able to detect large particles up to 10 μm, making it an interesting technique to measure large aggregates.
In theory both AUC and DCS can measure with high accuracy the particle size distribution of highly polydispersed samples within their working range, however it may be difficult to efficiently fractionate very small and large particles at the same time by choosing a fixed rotational speed. Recently, it has been shown that AUC experiments performed by using a rotational ramp composed of many speed steps, can help to overcome this problem, being able to analyze with high resolution very polydispersed samples [43, 44] .
The main limitation of centrifugal sizing techniques is that, to calculate the particle size distribution from the measured sedimentation coefficient, the density of the particle needs to be known and homogeneous over the whole population. This may limit AUC and DCS applicability to precisely measure the size of aggregates (or agglomerates), since it will be very difficult to selectively measure their density, which may be different from the density of the isolated particles. Changes in size caused by NP-protein interactions are difficult to measure due to changes in the density of the NP-protein complex. In these situations combining DCS measurements and accurate size measurements (for example with AF 4 -DLS) gives information on both the size of the complex and the thickness of the protein layer [45] .
Modern AUC instruments are equipped with both refractive index (RI) and/or absorbance detector(s), allowing to analyze other key parameters for NEP systems including drug loading [3, 46] . In typical NEP, the molecular weight of the active pharmaceutical ingredient (API) is much lower than the molecular weight of the nanoparticle carrier. In this case, the nanoparticles sediment much faster than the unbound API. If the unbound API possesses a specific UV-Vis absorption profile, then by choosing a centrifugal force which induce the sedimentation of the nanoparticle but not of the unbound API, a timeindependent and radius-independent absorbance background will be detected at the end of the analysis, when all the nanoparticles have sedimented. The latter signal is associated to the unbound API fraction in the sample. By estimating the absorbance detected at the beginning of the analysis, and the residual absorbance associated to the free API, both the unbound API and NEP-bound API fractions can be estimated in one simple run [3, 46] .
Indirect counting methods

Particle tracking analysis
Particle tracking analysis (PTA) is a single particles size measurement, that differently from batch mode DLS, does not overestimate larger aggregates or larger particles, allowing to measure the PSD of very complex samples. In PTA small size differences between particles or populations are measured by analyzing multiple high-resolution images generated by the light scattered by individual particles. The Brownian motion of each individual particle (diffusion) is captured by the instrument, and then transformed into a single particle diffusion coefficient. Finally, using the Stokes-Einstein equation, the hydrodynamic diameter is calculated, generating a high resolution numberbased PSD. A series of recorded videos of approx. 30-60 s is analyzed by the software, tracking frame by frame the center of each particles. The latest software development for PTA, the Finite Track Length Adjustment algorithm (FTLA), has significantly improved and simplified the measurements. The application of this algorithm is essential to achieve high resolution measurements, since it reduces size broadening, allowing to detect secondary peaks and to increase the resolution. Nowadays, the instrumentation is able to measure with high resolution the PSD of organic particles from 30 nm to 600 nm, while in the case of inorganic particles with a higher capability to scatter light, smaller sizes can be detected.
Interestingly, PTA can simultaneously measure the concentration of nanoparticles in addition to their size, as it counts individual particles in a field of view associated to a known volume. However the analysis of particle concentrations can be affected by the reduced field view of the camera, which limits the duration of the tracking and thus, the number of particles tracked. Regularly introducing fresh particles may help to increase the statistical robustness of the measurement [22] . In depth analysis of the principles and processes behind PTA and NTA is presented in Maguire et al., where a cause/effect is presented, the differences with DLS and the aspects linked to the advanced characterisation of polydispersed samples are also presented [22] .
Tunable resistive pulse sensing
Tunable Resistive Pulse Sensing (TRPS) is an indirect counting method based on the Coulter counter principle, which measures particle size, charge and concentration by resistive pulse sensing [47] . By combining selected pressure and voltage values, the particles suspended in an electrolyte medium (e.g. PBS buffer) are driven through a conductive membrane (nanopore), which is subjected to an applied electrical potential, and thus to an ionic current. The passage of each single particle induces a resistive pulse signal or "blockade" that is detected and measured by the software of the instrument. Particle volume is calculated from the magnitude of the pore blockage and then transformed into particle size, while surface charge and particle concentration can be derived from the blockade duration and blockade frequency. The instrument needs to be calibrated before each measurement with reference materials (usually polystyrene particles) of known size, concentration and surface charge. Hence, a reliable calibration is essential to provide robust and accurate size measurement, and care should be taken that the measurement conditions remain constant during calibration and while performing the sample measurement. The instrumentation covers a wide size range, being able to measure particles from 60 nm to 10 μm. It can be particularly interesting to measure big aggregates in the submicron range and TRPS can also be useful for quality control purposes (e.g. batch to batch comparison of particle size distribution, concentration and surface charge). 
Transmission electron microscopy
Electron microscopy (EM) techniques, e.g. transmission electron microscopy (TEM) and scanning electron microscopy (SEM), are indispensable tools for the characterisation of colloidal systems, including NEPs. EM is a direct counting method, which measures a size value for each particle selected for the analysis, thus providing a number-based particle size distribution. In the basic mode, the analysis of the images acquired by EM are based on a 2D projection of 3D particles. The most often used size value calculated by EM images is the diameter of a sphere having the same area as the 2D projected area associated to the 3D particle (e.g. diameter of an equivalent sphere possessing the same 2D projected area). Three dimensional reconstitution and 3D tomography methods also exist to create 3D images, combining the analysis of the same 2D objects taken by analysis the same slide from many different angles [48] . Specialized software help to analyze the images and to automate the very laborious counting process to determine the PSD, allowing to count a relatively large number of particles for a meaningful statistical analysis (ideally n > 500) [49] . Automated procedures have the potential to be significantly more efficient, accurate, and repeatable than human analysis, reducing the risk of user bias that can be introduced by manual particle selection and counting.
EM allows visualization of the NEPs, providing direct information not only on NEP size, but also on their shape and internal structure (morphology). Visualization of the particle shape is critical to complement and interpret the results obtained by other indirect sizing method, including light scattering and centrifugal measurements, which assume a spherical shape to calculate the particle size distribution (DLS, DCS & AUC) or need to define a shape to process the acquired data (MALS). Therefore, EM observations should always be included in the integrated analytical approach to characterise NEP systems. Unfortunately, EM measurements use complex and expensive instrumentation which requires highly trained personnel. For this reason, they may not be used in routine analysis (e.g. for batch to batch comparison). Among the EM techniques, TEM is the most widely used in the field of nanomedicine: it has been used to image inorganic NEP, liposomes, polymeric micelles, nano-emulsions, lipidic nanoparticles and nanovesicles [50] [51] [52] [53] . An appropriate sample preparation method should be carefully chosen and optimized in order to avoid the artificial modification of the sample prior to imaging. In presence of artifacts, the final images may show a completely modified structure which may not be representative of the NEP sample. For this reason, care should always be taken during the interpretation of the TEM images. Different techniques for sample preparation are available including drying, negative staining, freeze-fracture and cryo-TEM [50, 51, 53] . 
The EUNCL/NCI-NCL step by step approach
In our opinion, each measurement technique has its advantages and disadvantages and no single technique is capable to measure the particle size distribution of all the potential NEP systems under all the conditions which are relevant for pre-clinical studies. Therefore, the solution adopted, and here presented, by EUNCL and NCI-NCL is a multi-step approach, composed of three steps of incremental complexity, and based on the integration of multiple orthogonal measurements, as shown in Fig. 1 . A pragmatic and robust combination of the available assays should be selected on a case by case basis, by considering the nature of the NEPs, the expected size range and by balancing benefits and costs of the analysis.
Step1: Pre-screening
As a first step, a fast and simple measurement is performed to verify sample integrity and to detect major failures before engaging in more complex and time-consuming analysis. This pre-screening is particularly useful also to check sample stability in relevant clinical conditions (e.g. stability in the clinical buffers, stability vs time, major aggregation in presence of plasma proteins), and eventually to identify the conditions that induce a significant aggregation or degradation of NEPs, dramatically changing their PSD [27] . Batch mode DLS, or alternative fast and inexpensive techniques (e.g. PTA), may be suitable for the purpose since they quickly allow you to measure the size range and polydispersity of the NEP population in the sample [27, 28] .
If the measurement is performed according to a robust SOP [27, 28, 54, 55] , this approach can be widely adopted by all nanomedicine developers, in order to verify at every stage of their development the integrity of their product, its stability and to identify early failures. However, especially if batch DLS is used, even if the measured average size is within the expected range and polydispersity is low (PdI < 0.2) we suggest to proceed to a more complex analysis beyond this preliminary step. In fact, even the simplest case of what appears to be a stable NEP population which seems rather monodispersed by batch mode DLS can hide a more complex particle size distribution composed by multiple populations that could differs in size and shape and thus leading to different pharmacological outcome. An educational example was published by Hansen et al. [56] where the authors compared batch mode DLS and AF 4 -DLS resolution power by measuring the mixture of four 30-nm gold nanoparticles covered by various PEG moieties, thus differing in their hydrodynamic diameters. The batch-mode measurement was incapable to distinguish the single populations in the mixed sample and detected a single peak of a moderate with PdI < 0.17, which could be misinterpreted as a rather monodispersed sample composed by only one population, while by AF 4 -DLS the four populations were all resolved (Fig. 2) . The fact that batch mode DLS detected a single unresolved population demonstrated the limited resolution achievable by batch mode DLS even in cases of low polydispersity (PdI < 0.2), and thus emphasizes the importance of introducing a separation step (e.g. by AF4) that should be combined with DLS to individuate and characterise individual populations within a multimodal sample [56] .
Step 2: Analysis of PSD using high resolution techniques
As a second step, we strongly suggest combining two or more highresolution orthogonal techniques aiming at (i) resolving the PSD of the sample (ii) visualizing the particle morphology by EM (e.g. shape, complex structures etc) and (iii) eventually measure particle concentration (e.g. by NTA). Our view in this instance is to strongly recommend performing the analysis of PSD in relevant clinical conditions. Multiple high resolution techniques may be suitable for the purpose (see Table 1 ) and should be selected according to the nature of the sample (size range, surface charge, known density, particle shape) [31, 54, 57] . TRPS and NTA can be used to measure particle concentration in addition to PSD but they are only applicable if size is larger than 30 nm. AF 4 separation coupled with downstream DLS and MALS detectors is a very powerful alternative to measure the PSD distribution with high resolution over a wide size range, as described in [31] .
To illustrate the need for high resolution techniques, two nanoformulations were subjected to both batch-mode DLS and flow-mode DLS (AF 4 separation coupled with downstream DLS) for the determination of their PSDs, as illustrated in Fig. 3 . The batch-mode DLS results 4 separation with in-line DLS) DLS for dual drug-loaded liposomes (top panel) and loaded micelles (bottom panel). Batch-mode DLS measurements were made at 25°C after a 100-fold and 10-fold dilution in PBS for the dual drug-loaded liposomes and drug-loaded micelles, respectively. For flow-mode DLS, the z-average was measured across the peaks (green squares) using the Malvern Zetasizer and was based on an intensity threshold of > 240 kcps and > 200 kcps for the dual drug-loaded liposomes and drug-loaded micelles, respectively. The size ranges are given in the figure for each peak. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) for dual drug-loaded liposomes (top panel, Fig. 3) shows a polydispersed multimodal size distribution. The flow-mode DLS, after AF 4 elution optimization, mimics the batch-mode DLS in the sense that two major peaks are observed. However, with AF 4 -DLS, the size distributions are determined for each of these peaks. The first peak contains two size populations within this peak; a constant size population~31 nm on average (27-35 nm size range) and an increasing size population up to 100 nm. The second peak contains an increasing size population from 110 to 274 nm. The AF 4 -DLS results correspond very well with the batch-mode DLS results. However, the size distribution associated with the two peaks are now also known. In the second example (bottom panel, Fig. 3) , the batch-mode DLS of the drug-loaded micelles displayed a single broad peak with multiple size populations contained within. With flow-mode DLS, these broad overlapping size distributions observed in the batch-mode DLS measurements are now resolved. Two distinct size populations were observed; the first peak corresponded to a fairly constant size population of 55 nm whereas the second peak contained an increasing size population up to 235 nm. The results demonstrate that AF 4 , as a separation technique, is capable of resolving broad and polydispersed size populations, and when coupled with DLS detection, the size distribution can be measured as well.
Fig. 3. Comparison of batch-mode versus flow-mode (AF
Regulatory agencies recommend to always combine an indirect method with EM observations [7] . An illustrative example of the powerful combination of AF 4 -MALS-DLS and TEM is the characterisation of anionic liposomal formulations reported by Iavicoli et al. [58] . Their work demonstrated how the combination of AF 4 -DLS-MALS and TEM can reveal fine changes in the PSD and morphology of a formulation of anionic liposomes, e.g. when interacting with positively charged antimicrobial peptides. The AF4-MALS analysis of the complex formed between the peptides and the liposomes revealed the presence of additional populations of particles shifted to larger size values, in addition to the pristine liposomes (composed by unilamellar vesicles). Moreover, the value of the shape ratio (Rg/Rh), suggested the formation of a multilamellar phase in the larger population of particles, as also confirmed by TEM analysis. Again, batch mode DLS provided misleading results, since it was not able to identify the presence of multiple populations in the peptide-NP mixture and only showed one single population characterized by a broader PSD shifted to larger sizes.
The capability to synthetize multiple batches with consistent physico-chemical properties, including the PSD, is crucial for the successful translation of NEPs into the clinic. The NEP developers need to control the batch to batch variability of their products from the very early stages, since significant variation of the size and polydispersity between batches can affect their biological effects. The stability of the stock NEP during storage should also be investigated during the early development phases. In order to detect small changes in PSD, AF 4 -MALS-DLS, NTA or TRPS may be suitable options to be used in routine. In measuring the batch-to-batch variability of NEPs, it is extremely important to choose the correct sizing technique, one that is sensitive enough to detect small size variations. For example, three lots of PEGylated metal oxide nanoparticles were initially assessed for size and morphology by TEM. TEM was chosen over DLS in this case as TEM is typically used for metallic nanoparticle sizing as well as the technique being able to measure the morphology at the same time. Representative TEM images along with their size summary are shown in Fig. 4 . As can be seen by both the TEM images and size analysis, all three lots look similar. If one were to only perform TEM as the sizing technique, all three lots would have no batch-to-batch variation. However, further analysis utilizing AF 4 coupled with MALS detection (an example of a high-resolution technique) revealed different conclusions. The resulting fractogram is given in Fig. 4 and shows that all three lots consist of a wide range of sizes. Moreover, two lots were identical while lot 1 was smaller. Thus, in this case, using AF 4 -MALS, all three lots were not identical. This example highlights three significant issues: the importance of selecting the correct sizing technique to control batch to batch variability, the importance of utilizing orthogonal sizing techniques, and the need for employing at least one high-resolution sizing technique.
In another example, three lots of PEGylated metal core-shell [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] nanoparticles were examined by TRPS for batch to batch variability. In this case, both size and zeta potential were measured for each particle and the results shown in Fig. 5 . As shown in the figure, lot 1 had a more uniform size and zeta potential distribution compared to the other two lots which were similar. Such information (i.e. per particle) would not be possible by batch-mode DLS and zeta potential measurements. When there are discrepancies between results obtained by orthogonal techniques, when it is difficult to resolve the PSD of the sample (e.g. to differentiate between larger particles and multimers), or if a very large size range needs to be covered (e.g. if few very large aggregates are detected), the combination of multiple high resolution techniques (three or more) may be advisable to get a more accurate picture.
In heterogeneous samples, it could be difficult to understand the origin of sample polydispersity. In particular, it may be challenging to understand if population of larger sizes are composed by larger single particles or by small aggregates of the main population. The capability of different techniques to recognize the presence of dimer and multimers was investigated by Mehn et al. [20] , by considering the potential of single and combined complementary sizing techniques. In this work, a bimodal sample of polystyrene particles was analyzed by AUC, DCS, NTA, AF 4 -MALS-DLS, TRPS and cryo-TEM. The presence of dimers and multimers was unquestionably proven by the combination of TEM imaging after FFF separation. Interestingly, AF 4 -MALS-DLS, and centrifugal methods including AUC and DCS were able to give indirect information on particle shape, suggesting the presence of dimers made of rigid spherical nanoparticles instead of larger particles.
The detection of a small amounts of very large aggregates (> 1 μm) in a NEP mixture is another nontrivial task, where the use of multiple orthogonal techniques is highly recommended in order to cover a wide size range. To illustrate this point, multiple orthogonal sizing techniques were employed to detect the presence of large aggregates in a lipid-protein nanovesicle formulation, as reported by Grossman et al. [12] . Results for batch-mode DLS, laser diffraction, and AF 4 coupled with MALS, UV, and DLS, are presented in Fig. 6 . By batch-mode DLS (top panel, Fig. 6 ), a very broad size distribution ranging from approximately 20 nm to over a micron, was observed, with 87 nm being the major peak size. Although the broad size distribution indicates that size populations above a micron exist, DLS cannot accurately measure sizes on the micron scale as they generally settle to the bottom of a cuvette over time, making those particles inaccessible to the laser without agitation. DLS is based on Brownian motion and particles that are settling cannot be interpreted correctly. With laser diffraction, this is not the case and agitation is possible. Laser diffraction analysis (middle panel, Fig. 6 ) showed two size populations; one at approximately 100 nm, and a second size population at approximately 7.7 μm. The laser diffraction size of the smaller population is in good agreement with the DLS data. Furthermore, laser diffraction was able to confirm the presence of a larger size population, and provide a measured size for this population, which DLS could not. A third technique, AF 4 -DLS-MALS-UV, was used to further asses the presence of aggregates. As this represents a high-resolution technique, more information was obtained compared to the previous two techniques. The AF 4 fractogram (bottom panel, Fig. 6 ) showed three populations based on the UV, MALS, and DLS signals, namely free protein, lipid-protein nano-vesicles, and lipid aggregates. As demonstrated by this example, multiple orthogonal techniques are needed to better assess the particle size distribution of a NEP. Moreover, the higher the resolution of the technique, the more information and understanding of the NEP can be obtained.
Step 3: Stability of particle size in biological media
As recently reported by the FDA [7] , after entering into the systemic circulation, the bound plasma proteins may endow nanomaterials with new biological properties, including the modification of the PSD, which may affect NEP safety and efficacy profile and, thus, should be considered a quality attribute. Interaction of the NEPs with plasma proteins may induce various effects on the particle size, depending on the properties of the NEP system, including the increase of the particle size of a few nanometres due to the formation of a protein corona on the particle surface, or more drastic size changes due to aggregation, disaggregation or destabilization of the particles. Therefore, as a third step, our suggestion is the investigation of the effects of the interaction of NEP with plasma proteins on particle size.
The reader should be aware that, since every NEP is different, the range of PSD for safety and efficacy of each formulation will vary depending on the nature of the NEP and on its specific clinical application. Is not the scope of this article trying to specify the appropriate/ allowable PSD range for each NEP system. The main aim of this section is to discuss the EUNCL and NCI-NCL strategy to assess fine or major changes in PSD of NEPs in complex media. The reader should also be aware that other critical quality attributes should be assessed in complex media, including the chemical stability of the particles, their degradation products and, in presence of an API, the drug release profile.
To further explore those aspects, the reader could refer to the following references [3, 6, 7, 12, 12, 15, 46, [59] [60] [61] . The sizing analysis in complex media requires the use of high-resolution techniques due to the complexity of the nanoparticle and protein mixture. Two illustrative examples that discourage the use of the low-resolution batch mode DLS, and propose the AF 4 -DLS-MALS as a suitable alternative are reported below.
Gioria et al. [3] measured the PSD of a Doxorubicin liposomal formulation before and after incubation with plasma by batch mode DLS and AF 4 -DLS-MALS for comparison purposes. According to AF 4 -DLS-MALS the average particle size of the liposomal formulation was not modified by the presence of plasma proteins, confirming the known stability of PEGylated liposomal samples in physiological conditions. On the contrary, the batch mode DLS analysis was biased toward smaller size simply because the instrument was not able to resolve the signal of the serum proteins (smaller size) from the contribution of the liposomal population. The study showed that AF 4 -MALS DLS, due to the fractionation step performed before the detection, can often separate serum proteins from the NEP populations, and therefore is an interesting option to detect and quantify the small changes in the PSD after the incubation of NEPs with plasma.
The protein layer absorbed on the particle surface cannot be detected by TEM. However, if major changes in PSD are detected by indirect measurements after incubation with serum proteins, e.g. due to particle degradation, the changes in the particle physical properties may be visualized by electron microscopy. Caputo et al. have recently compared the potential of batch mode DLS, TEM and AF 4 -DLS to detect fine modification of lipid-based nanoparticle size in the presence of plasma proteins [62] . Interestingly, by AF 4 -MALS and the TEM analyses the authors were able to measure a fine change in particle size (PSD narrower and shifted to smaller sizes), while batch mode DLS was not able to resolve any difference (Fig. 7) .
Other high resolution techniques, including centrifugation techniques, NTA or TRPS may be useful to investigate the stability of NEP in biological media that contains plasma proteins. For example, AUC and DCS may give very informative results on both major changes of the sedimentation coefficient (and thus indirectly on particle size) and of drug release in presence of plasma proteins with one single measurement [3] . Therefore, they may be interesting techniques in some specific cases to study aggregation and drug release. However, in the presence of plasma adsorbed to the particle surface the density of the particles may change (especially in the case of inorganic particles) and needs to be measured independently.
SOPs and quality control
In order to perform robust characterisation in line with the regulatory needs [7] the methodologies and techniques to adopt should be selected considering their overall applicability and suitability, in order to provide robust and reliable data. The techniques chosen should be able to measure the size range of interest and the sample should not be unintentionally altered/modified/transformed by the measurement (see Table 1 ). Thus, the sampling of NEP should be performed in a representative state of the process stage being evaluated, and the sample preparation should be adequately controlled to ensure that the process do not substantially change its properties [7] . Importantly, suitable quality controls should be applied to verify the working condition of the instruments, the calibration status and also the detection limits of the selected techniques. For example, in case of samples composed of multiple populations, specific pseudo-polydispersed control samples (e.g. artificial mixtures of polystyrene control particles in the same size range) could be tested to evaluate capacity of the method of choice to resolve multiple populations in a specific size range. The use of validated methods and of SOPs with a defined specific measurement purpose is strongly recommend, and to this end the SOPs from EUNCL & NCI-NCL are freely available to be adopted and used at http://www.euncl.eu/about-us/assay-cascade/ & at https://ncl.cancer. gov/resources/assay-cascade-protocols).
Conclusions and perspectives
To the best of our knowledge, there is not a single sizing technique which can resolve and provide all the relevant information needed for pre-clinical studies. Batch mode DLS is suitable to detect major issues with sample integrity and stability at early stages, however it is hardly applicable as the only method to characterise the size and polydispersity of complex NEP. EM is the only direct technique that allows to visualize polydispersed samples over a wide size range, and thus providing direct shape information. However, limitations do exist since the sample preparation is often critical and may introduce artifacts and cannot prevent sample aggregation. Furthermore, imaging observation, recording and data analysis can be prolonged and user-biased. This makes EM difficult to be adopted as a technique for routine checks. NTA, TRPS, DCS and AUC are cost-effective and easy to use alternatives which can provide satisfactory resolution for polydispersed samples e.g. for batch to batch variability and stability checks. However, the centrifugal techniques are only applicable when the density of the particles is known, while NTA is not suitable for small organic particles below 30 nm. AF 4 -DLS-MALS is another interesting alternative to analyze NEP in routine and to detect changes in PSD caused by interactions with plasma. Unfortunately, method development may be time consuming, and some samples may suffer from irreversible loss on the membrane in the fractionation channel. The solution presented by EUNCL and NCI-NCL is a incremental multi-step approach which consists of a quick preliminary step to verify sample integrity and stability by low resolution techniques (prescreening), followed by the combination of complementary high resolution sizing measurements performed in simple buffers and complex biological environments, which mimics the conditions encountered by NEPs during their clinical administration (e.g. reconstitution buffer, behavior in plasma). We have demonstrated the need for employing at least one high-resolution sizing technique, the importance of selecting the correct sizing techniques for the purpose, and the robustness of utilizing orthogonal sizing techniques to study the physical properties of the complex samples. The use of orthogonal techniques allows to measure the particle size distribution of complex polydispersed materials, which are very common in the nanomedicine and pharmaceutical industry. In this context, we have demonstrated that the combination of EM, AF 4 -DLS-MALS, AUC, TRPS is able to (i) discriminate between populations of particles characterized by different sizes and shapes (ii) distinguish larger particles from small aggregates, (iii) resolve small changes of PSD caused by a not reproducible synthetic procedures (batch to batch variability) and/or by NEP instability upon storage and (iv) study the influence of biological environments to average particle size and polydispersity, which are crucial to understand the biological effects and physiological stability of NEP in vitro and in vivo. Other orthogonal sizing techniques, including SAXS/WAXS, AFM, sp-ICP-MS may also be applicable according to the nature of the NEPs. The choice of the specific techniques to be adopted for each NEP should be defined on a case by case basis according to the nature of the sample and of the complexity of its PSD. However, according to the authors, by adopting a characterisation approach of incremental complexity and by using orthogonal methods from the early phases of product development, a robust sizing characterisation helps to identify the physical property of the product and eventually to detect early fails, thus reducing the cost of development and speeding up the translation of the promising NEP into the clinic. It is encouraging to see a mind-change from the experts and regulators which are starting to support the orthogonal approach for the physico-chemical characterisation of NEPs. In the recent years, thanks to commitment, efforts and tight collaboration of experts, regulatory agencies and metrology institutes, there has been an increase in the number of orthogonal techniques, including NTA, cryo-TEM and AF 4 which have been standardized by ISO and ASTM International, and thus introduced for quality controls (QC) and acceptance (QA) across the stakeholders [4] . Nonetheless, these are impacting the R&D in terms of manufacturing and QC/QA costs and thus forcing industry to often adjust to their limited financial levels and thus to rely, or adopt, limited characterisation steps. This has been, for instance, the case for the use of batch mode DLS as the only sizing measurement. The extensive and comprehensive work carried out by EUNCL and NCI-NCL, not only support knowledge sharing and open access for SOPs and protocols, but also provides a platform for educating the community and offering free of charge and unbiased access to their state of the art characterisation services. In this matter, we believe, the use of incremental complexity orthogonal techniques for the characterisation of NEPs will have a positive impact in terms of scale-up effectiveness, industrialization cost, and time to market for any current and future nanotechnology-based medicinal products.
